XM does not provide services to residents of the United States of America.

Europe before the bell: appetite for tech, bank results



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>LIVE MARKETS-Europe before the bell: appetite for tech, bank results</title></head><body>

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com


EUROPE BEFORE THE BELL: APPETITE FOR TECH, BANK RESULTS

Even though Microsoft MSFT.O failed to impress high Wall Street expectations, with growth in its cloud business falling a little short of what analysts had estimated, appetite for tech looked strong again on Wednesday following July's rout.

Futures on the tech-heavy Nasdaq NQc1 rose over 1.4% first thing in European hours as chip designer AMD AMD.O lifted its 2024 forecast for AI chip sales and said supplies would remain tight through 2025.

Dutch group ASML ASML.AS meanwhile surged over 7% in early Frankfurt trade after Reuters reported that the new U.S. rule on foreign chip equipment exports to China will exempt some allies, including Japan, the Netherlands and South Korea.

In Europe, the focus was on banks too, following results from London-listed heavyweight HSBC HSBA.L, coming just as the sector .SX7P reclaimed this month from tech .SX8P the top stop in STOXX rankings, with a YTD surge of over 21%.

HSBC pledged to buy back $3 billion in shares after reporting stable H1 profit on growth in wealth management and narrowing loss in Chinese real estate. Its Hong-Kong listed stock rose over 3% on the announcement.

In Spain, BBVA BBVA.MC reported a 38% rise in Q2 net profit thanks to a solid domestic performance, where it wants to buy smaller rival Sabadell SABE.MC to reduce its reliance on Mexico, its main market.

Besides tech and banks, it was another heavy day for earnings releases in Europe.

Among the early releases, airline Lufthansa LHAG.DE forecast an earnings slump as costs rise, adding to gloomy updates in the sector. Drugmaker GSK GSK.L raised its forecasts after beating quarterly expectations boosted by its cancer and HIV portfolio.

EuroSTOXX50 STXEc1 futures rose 1%


(Danilo Masoni)

*****



EARLIER ON LIVE MARKETS:

BOJ HIKES, FED NEXT CLICK HERE


</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.